AbstractDuring the last decades, sublingual allergen immunother-apy (SLIT) has been developed as an alternative to subcuta-neous allergen immunotherapy (SCIT). According to severaloriginal Cochrane Review, questions remained about thesafety and efficacy of sublingual immunotherapy for peoplewith asthma .Despite that, many guidelines for asthma treatment rec-ommend that SLIT be used for people with asthma that isdifficult to control with standard therapies [2, 3, 4, 5].Since polysensitization to various allergens is quite com-mon in bronchial asthma, choosing vaccines for specific im-munotherapy is usually challenging . It is also interestingto see how effective immunotherapy with dominant aller-gens can be in patients of different demographic groups andthe cost-effectiveness of this approach .The study aimed to evaluate the efficacy, effectivenessand safety of sublingual immunotherapy with dominant al-lergens in poly sensitized patients. The research was con-ducted in several stages. In the first stage, a prospectivecohort study was performed. Patients of both sexes aged 6-60 years with asthma who were sensitized to dominant respi-ratory allergens were selected. They were placed in twogroups. The active group (SLIT) and the control (standardcare) group included patients (129) who were sensitized tomite, molds and mixed-grass types of allergens to only onetype of allergen.
Download data is not yet available.